

Presentation of the proposed Board

The Nomination Committee's proposal for the Board of Directors of BioArctic AB prior to the Annual General Meeting 2019

NEW ELECTION

Ewa Björling (1961)

Proposed as director:	2019
Holdings in BioArctic:	-
Education:	Lecturer, MD, licensed dental practitioner, Karolinska Institutet
Other current assignments:	Chairman of the board of SPBI (Swedish Petroleum and Biofuel Institute), director of Essity AB, Biogaia AB and Mobilaris AB.

Ewa Björling is independent in relation to the company, its executive management and the major shareholders of the company.

RE-ELECTION

Wenche Rolfsen (1952)

Proposed chairman of the Board

Director since:	2016
Holdings in BioArctic:	19,905 B-shares and call options entitling to the acquisition of 27,270 B-shares
Education:	Pharmacist, Doctor of pharmacy (pharmacognosy), Adjunct Professor at Uppsala University, Sweden
Other current assignments:	Chairman in InDex Pharmaceuticals Holding AB and InDex Pharmaceuticals AB, board member of Swedish Match AB, Recipharm AB, InDex Diagnostics AB and CEO and board member of Rolfsen Consulting AB. Partner in Serendipity Partners.

Wenche Rolfsen is independent in relation to the company, its executive management and the major shareholders of the company.

Ivar Verner (1947)

Deputy chairman since:	2017
Board member since:	2010
Holdings in BioArctic:	72,500 B-shares through Förvaltningsaktiebolaget Kanalen AB and call options entitling to the acquisition of 27,270 B-shares
Education:	Master of Business Administration, Stockholm School of Economics, Sweden
Other current assignments:	Chairman of Erlandsons Brygga AB, Centrum Fastigheter i Norrtälje AB, Norrländska Gruppbestäder Holding AB, Tegnér & Son AB, Firren AB and Valsättra Exploaterings AB. Board member of Förvaltningsaktiebolaget Kanalen, Verner & Partners AB and Valsättra Tomter AB.

Ivar Verner is independent in relation to the company, its executive management and the major shareholders of the company.

Hans Ekelund (1948)

Director since: 2014
Holdings in BioArctic: 42,500 B-shares through Ekarna Invest AB and call options entitling to the acquisition of 27,270 B-shares
Education: Master of Business Administration, Stockholm School of Economics, Sweden
Other current assignments: Chairman of Connect Öst (non-profit organization) and board member in Ekarna Invest AB.

Hans Ekelund is independent in relation to the company, its executive management and the major shareholders of the company.

Pär Gellerfors (1947)

Director since: 2003
Holdings in BioArctic: 5,759,998 A-shares and 15,232,989 B-shares through Ackelsta AB
Education: Bachelor degree in chemistry at Stockholm University 1967; PhD in chemistry at Stockholm University 1977; Associate Professor of Biochemistry at Stockholm University 1983, Sweden
Other current assignments: CEO and board member in Swenora Biotech AB, board member of Ackelsta AB and LPB Sweden AB and deputy board member of Otwomed AB

Pär Gellerfors is controlling 23.8 percent of the share capital and 33.5 percent of the votes in the company and has previously been active in the company's management. Pär Gellerfors thereby is not independent in relation to the company, its executive management nor the major shareholders of the company.

Lars Lannfelt (1949)

Director since: 2003
Holdings in BioArctic: 8,639,998 A-shares and 22,848,159 B-shares through Demban AB
Education: Medical degree 1978; specialist in psychiatry 1987; doctoral thesis at Karolinska Institutet 1990; Associate Professor of Neurogenetics at Karolinska Institutet 1993; specialist in geriatrics 2000, Sweden
Other current assignments: Board member of Demban AB and LPB Sweden AB

Lars Lannfelt is controlling 35.8 percent of the share capital and 50.2 percent of the votes in the company and is employed in the company. Lars Lannfelt thereby is not independent in relation to the company, its executive management nor the major shareholders of the company.

Mikael Smedeby (1968)

Director since: 2018
Holdings in BioArctic: 10,000 B-shares and call options entitling to the acquisition of 27,270 B-shares
Education: Master of Laws, Uppsala University, Sweden
Other current assignments: Chairman of the board in Hanza Holding AB, Coeli Holding AB, Salléngruppen AB. Board member of Uppsala Innovation Centre AB, Disruptive Materials AB and Motion Display Scandinavia AB

Mikael Smedeby is independent in relation to the major shareholders of the company.
Mikael Smedeby is not independent in relation to the company, its executive management as a result of Advokatfirman Lindahl's assignment as advisors to BioArctic.

Eugen Steiner (1954)

Director since: 2017
Holdings in BioArctic: 40,000 B-shares through Setraco AB and call options entitling to the acquisition of 27,270 B-shares
Education: Medical doctor, Ph.D in clinical pharmacology at Karolinska Institutet, Sweden
Other current assignments: Board member in Apotek Produktion & Laboratorier AB, Inbox Captial AB, Karolinska Institutet Holdings AB, Karolinska Institutet Innovations AB, Stiftelsen Forska!Sverige, Stockholm School of Entrepreneurship and Setraco AB. Deputy board member of Doctrin AB

Eugen Steiner is independent in relation to the company, its executive management and the major shareholders of the company.

The information regarding board assignments and holdings of shares is as of 31 December 2018 and also includes any changes thereafter known to the company.